Bullish option flow detected in Pfizer with 133,446 calls trading, 6x expected, and implied vol increasing over 5 points to 37.78%. Jul-20 36 calls and Aug-20 37 calls are the most active options, with total volume in those strikes near 20,300 contracts. Earnings are expected on July 28th.
A senior Trump administration official said that U.S. health officials and drugmakers anticipate starting to make potential COVID-19 vaccine doses by the end of the summer, CNBC’s Berkeley Lovelace, Jr. reports. The U.S. is seeking to deliver 300M doses of a coronavirus vaccine by early 2021, and the manufacturing process is already underway even though they aren’t sure which vaccine, if any, will be effective, the author says, citing a senior Trump administration official. “Exactly when the vaccine materials will be in production and manufacturing? It’s probably four to six weeks away,” the official said on a call with reporters, which was hosted by the Department of Health and Human Services. “But we will be actively manufacturing by the end of the summer.” Publicly traded companies working on vaccines include Moderna (MRNA), Johnson & Johnson (JNJ), Inovio (INO), Pfizer (PFE), BioNTech (BNTX), Novavax (NVAX), Merck (MRK), Sanofi (SNY), and GlaxoSmithKline (GSK).
CNBC’S Morgan Brennan takes a look at pharmaceutical as Pfizer’s positive vaccine news has led the sector higher. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2NGeIvi